CPHI Podcast Series: From Patents to Public Health: The GLP-1 Journey

The latest episode of the CPHI Podcast Series delves into the future of obesity management globally, offering opinins on might happen after patent expirys and new globals players entering the fray. 

In this insightful episode, we explore the transformative role of GLP-1 therapies in clinical obesity treatment and the technological advancements driving their success.

Aurelio's focus is on global markets where he generates evidence-led insights with a view to spark high-level discourse on various topics relevant to the pharmaceutical industry and speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects. He is considered a subject matter expert in several areas including Biosimilars, Sustainability and Innovative Launches.

During this episode, Aurelio delves into how these medications are revolutionising care, offering hope to millions worldwide. A key focus is the upcoming patent expiry of semaglutide in 2026, which could significantly impact affordability and global access, sparking discussions on equitable distribution.

The conversation shifts to the global health challenge posed by rising obesity rates in countries like India, China, Brazil, and South Africa. Aurelio highlights the barriers to accessibility in these regions and discusses strategies for making GLP-1 therapies more widely available, including regulatory frameworks, infrastructure development, and stakeholder collaboration.

We also examine how pharmaceutical companies can address the surging demand for GLP-1s while ensuring fair access, particularly in lower-income countries. The episode concludes with a forward-looking discussion on the potential of small molecules to replace polypeptides in obesity treatments, exploring their benefits, challenges, and applicability to other disease burdens.

Tune in here to learn how GLP-1s are reshaping public health strategies and what the future holds for anti-obesity medications in tackling the global obesity epidemic.